Skip to content

    Coherus Oncology (CHRS) stock price & financials

    View CHRS earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+23.7% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $6.05M
    $7.73M
    $7.60M
    $10.25M
    $11.57M
    +91.2%
    $12.75M
    +64.9%
    $12.31M
    +62.0%
    $14.31M
    +39.5%
    Strengthening
    Operating Profit
    -$46.86M
    -$45.38M
    -$45.44M
    -$45.49M
    -$44.33M
    +5.4%
    -$45.88M
    -1.1%
    -$36.15M
    +20.4%
    -$32.33M
    +28.9%
    Strengthening
    Net Profit
    -$10.75M
    -$50.70M
    -$56.57M
    $297.77M
    -$35.53M
    -230.5%
    -$37.64M
    +25.7%
    -$38.33M
    +32.2%
    -$20.63M
    -106.9%
    Weakening
    EPS
    $-0.09
    $-0.49
    $2.57
    $-0.31
    -244.4%
    $-0.28
    +42.9%
    $-0.13
    -105.1%
    Weakening
    Other Income
    Interest
    $2.83M
    $727.0K
    $2.15M
    $2.28M
    $2.33M
    -17.8%
    $2.25M
    +209.4%
    $2.19M
    +1.7%
    $2.32M
    +2.0%
    Strengthening
    Depreciation
    Profit before Tax
    -$47.60M
    -$44.91M
    -$47.40M
    -$44.86M
    -$44.52M
    +6.5%
    -$46.35M
    -3.2%
    -$36.94M
    +22.1%
    -$33.35M
    +25.7%
    Strengthening
    MarginsOPM
    -774.2%
    -586.9%
    -597.9%
    -443.6%
    -383.1%
    +50.5%
    -359.9%
    +38.7%
    -293.7%
    +50.9%
    -226.0%
    +49.1%
    Strengthening
    Tax
    ReturnsROIC
    0.7%
    3.5%
    3.9%
    -20.3%
    2.4%
    +230.5%
    2.6%
    -25.7%
    2.6%
    -32.2%
    1.4%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$72.36M$177.67M$541.16M$417.19M$63.55M$102.89M$125.99M$88.88M$82.92M
    Short-Term Investments$0$0$128.13M$14.86M$83.25M$22.38M
    Total Current Assets$84.43M$343.01M$767.48M$602.32M$381.23M$475.63M$341.58M$206.71M$133.79M
    Net PP&E$6.66M$16.49M$20.06M$16.01M$14.44M$11.03M$7.09M$4.30M$865.0K
    Goodwill$943.0K$943.0K$943.0K$900.0K$943.0K$943.0K
    Intangibles$2.62M$2.62M$2.62M$3.56M$5.93M$71.67M$24.79M$20.00M$18.75M
    Total Assets$99.47M$408.93M$841.65M$679.33M$480.85M$629.60M$448.53M$258.34M$191.18M
    LiabilitiesTotal Current Liabilities$33.26M$114.97M$145.65M$165.33M$138.69M$331.77M$282.98M$140.39M$75.51M
    Short-Term Debt
    Long-Term Debt$0$73.66M
    Long-Term Leases$0$10.26M$9.07M$6.75M$3.63M$4.98M$3.29M$1.46M$459.0K
    Total Liabilities$138.06M$303.71M$560.67M$581.61M$618.26M$823.03M$580.52M$197.33M$130.34M
    EquityCommon Stock & APIC$7.0K$7.0K$7.0K$7.0K$8.0K$11.0K$12.0K$12.0K$15.0K
    Retained Earnings-$984.83M-$895.00M-$762.75M-$1.05B-$1.34B-$1.58B-$1.55B-$1.38B-$1.44B
    Total Equity-$38.59M$105.21M$280.97M$97.73M-$137.42M-$193.43M-$131.99M$61.01M$60.84M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$159.27M$28.36M$154.15M-$37.43M-$241.12M-$174.88M-$20.44M-$138.51M-$186.03M
    Cash from Investing-$1.19M-$12.73M-$14.40M-$138.41M-$166.85M$144.64M$230.32M$375.09M-$9.78M
    Cash from Financing$105.42M$89.37M$223.95M$51.88M$54.33M$69.60M-$186.97M-$273.70M$61.82M
    SummaryCapital Expenditure-$789.0K-$1.82M-$7.23M-$1.29M-$2.04M-$286.0K
    Free Cash Flow-$160.06M$26.53M$146.91M-$38.72M-$243.16M-$175.17M
    FCF Margin7.5%30.9%-11.9%-115.2%-68.1%

    Ratios